Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

Beijing Primegene Therapeutics Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria and asthma.

A safety net health care provider has won a $10.3 million interim arbitration judgment against Eagan-based Prime Therapeutics over price-fixing allegations between the local pharmacy benefits manager ...